1h Free Analyst Time
Glycoprotein 41 (gp41) pipeline Target constitutes close to 19 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The latest report Glycoprotein 41 - Drugs In Development, 2022, outlays comprehensive information on the Glycoprotein 41 (gp41) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.Speak directly to the analyst to clarify any post sales queries you may have.
Glycoprotein 41 (gp41) - Gp41 or glycoprotein 41 is a transmembrane protein that contains several sites within its ectodomain that are required for infection of host cells. It is a subunit of the envelope protein complex of retroviruses. The interaction of gp41 fusion peptides with the target cell causes a formation of an intermediate structure which bridges and fuses the viral and host membranes together. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 2, 5 and 1 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 2, 1 and 5 molecules, respectively. Report covers products from therapy areas Infectious Disease which include indications Human Immunodeficiency Virus (HIV) Infections (AIDS).
Furthermore, this report also reviews key players involved in Glycoprotein 41 (gp41) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Glycoprotein 41 (gp41)
- The report reviews Glycoprotein 41 (gp41) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Glycoprotein 41 (gp41) targeted therapeutics and enlists all their major and minor projects
- The report assesses Glycoprotein 41 (gp41) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Glycoprotein 41 (gp41) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Glycoprotein 41 (gp41)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Glycoprotein 41 (gp41) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Report Coverage
- Glycoprotein 41 (gp41) - Overview
- Glycoprotein 41 (gp41) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Glycoprotein 41 (gp41) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Glycoprotein 41 (gp41) - Companies Involved in Therapeutics Development
- Frontier Biotechnologies Inc
- Longevity Biotech Inc
- MacroGenics Inc
- Minka Therapeutics SA
- Molecular Express Inc
- Mymetics Corp
- Navigen Inc
- Novodux
- Osel Inc
- Protheragen Inc
- Glycoprotein 41 (gp41) - Drug Profiles
- albuvirtide LA - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Cl3hmAb - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CPT-31 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- DS-007 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- HIV-1 vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- human immunodeficiency virus (virus like particles) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- LBT-5001 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- MGD-020 - Drug Profile
- Product Description
- Mechanism Of Action
- Monoclonal Antibodies to Target GP120 and GP41 for HIV - Drug Profile
- Product Description
- Mechanism Of Action
- Monoclonal Antibody to Target GP41 for HIV Infections - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- MPER-656 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- MYMV-101 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Recombinant Peptides to Inhibit gp41 for HIV-1 Infection - Drug Profile
- Product Description
- Mechanism Of Action
- Recombinant Protein to Inhibit Glycoprotein 41 and Glycoprotein 120 for Infectious Disease - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecules to Target GP120 and Gp41 for HIV-1 Infections - Drug Profile
- Product Description
- Mechanism Of Action
- Synthetic Peptides to Inhbit GP41 for HIV Infections - Drug Profile
- Product Description
- Mechanism Of Action
- Synthetic Peptides to Inhibit GP120, GP41, Tat, Integrase and Protease for HIV-1 Infection - Drug Profile
- Product Description
- Mechanism Of Action
- VAC-02 - Drug Profile
- Product Description
- Mechanism Of Action
- VAC-3S - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Glycoprotein 41 (gp41) - Dormant Products
- Glycoprotein 41 (gp41) - Discontinued Products
- Glycoprotein 41 (gp41) - Product Development Milestones
- Featured News & Press Releases
- Dec 27, 2021: Frontier Bio's 'Spring Breeze Program' is dedicated to the treatment of AIDS patients in low-income areas
- Nov 26, 2021: 'China AIDS Diagnosis and Treatment Guidelines (2021 Edition)' introduces Aikening as a recommended treatment plan for post-exposure prevention of AIDS
- Oct 27, 2021: Frontier Biotechnologies long-acting injectable (Aikening(R)), in a two drug regimen, proves safe and effective for critically ill hospitalized AIDS patients
- Jul 19, 2021: Frontier biotechnologies first long-acting injectable (Aikening), in a two drug regimen for HIV, proves safe and efficacious for patients
- Dec 10, 2019: Navigen announces FDA clearance of its IND application to initiate first-in-human studies for CPT31, a novel, D-peptide HIV entry inhibitor
- Apr 29, 2019: Mymetics receives funding from NIH for Novel HIV Vaccine Study
- Aug 21, 2018: Frontier Biotech's novel long-acting, all-injectable anti-HIV two-drug combo IND allowed by the US FDA
- Jun 07, 2018: Frontier Biotech receives marketing authorization from China FDA for Aikening (albuvirtide for injection), China's first new drug for the treatment of HIV
- Sep 18, 2017: Navigen Awarded $4.9MM to Advance its HIV Entry Inhibitor CPT31
- Sep 13, 2017: Mymetics to Present New Preclinical Data on Thermostable and Cold-Chain Independent Virosome based Vaccines
- Jul 26, 2017: Navigen Presents Promising Pre-Clinical Data on CPT31 at the 9th International AIDS Society Conference on HIV Science
- Oct 20, 2016: Dr. Michael Kay Presents Recent Data on Navigen’s HIV Entry Inhibitor, CPT31, at the 2016 HIVR4P meeting
- Sep 19, 2016: Mymetics and Texas Biomedical Research Institute Continue Collaboration on HIV Vaccine Development
- Aug 24, 2016: Navigen Awarded $500,000 Grant to Support Depot Formulation of its HIV Drug Candidate
- Jun 06, 2016: Frontier Biotech Long-acting HIV-1 Fusion Inhibitor Albuvirtide Meets 48-Week Primary Objective: Interim Results of a Phase 3 Trial
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indication, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products under Investigation by Universities/Institutes, 2022
- Products under Investigation by Universities/Institutes, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pipeline by Frontier Biotechnologies Inc, 2022
- Pipeline by Longevity Biotech Inc, 2022
- Pipeline by MacroGenics Inc, 2022
- Pipeline by Minka Therapeutics SA, 2022
- Pipeline by Molecular Express Inc, 2022
- Pipeline by Mymetics Corp, 2022
- Pipeline by Navigen Inc, 2022
- Pipeline by Novodux, 2022
- Pipeline by Osel Inc, 2022
- Pipeline by Protheragen Inc, 2022
- Dormant Products, 2022
- Discontinued Products, 2022
- Number of Products under Development by Stage of Development, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Frontier Biotechnologies Inc
- Longevity Biotech Inc
- MacroGenics Inc
- Minka Therapeutics SA
- Molecular Express Inc
- Mymetics Corp
- Navigen Inc
- Novodux
- Osel Inc
- Protheragen Inc
